• Clinical trials have shown that as well as treating obesity, Qnexa could also be used to help sufferers of sleep apnoea, a frustrating condition where the nasal passages narrow during sleep, causing sufferers to wake up regularly with a ... [view original]

• 07:03 AM Eastern Standard Time, 03/08/2010 (MidnightTrader) — VIVUS (VVUS) announced the issuance of three additional patents by the US Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the ... [view original]

• Experts claim that patients can lose as much weight with Qnexa as they would if they had obesity surgery. Dr Kishore Gadde, director of obesity clinical trials at Duke University in North Carolina, who led the study, said: “The weight ... [view original]

• Clinical trials have shown that the Qnexa diet pill is effective and safe. This weight loss drug is taken by mouth, once a day. It's got a tiny dose formulation, so its manufacturer claims that it is well endured by its users. ... [view original]

• VIVUS announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa, our investigational drug candidate, for the treatment of obstructive sleep apnea (OSA). This study demonstrated statistically significant ... [view original]

• (Nasdaq: VVUS) today announced the issuance of three additional patents by the US Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents. [view original]

• tags: Qnexa Forum, Qnexa, Qnexa Before and After Pictures, Qnexa Side Effects,. no comments. [view original]

• One of these products is stronga title=qnexa href=http://www.obesitydietpill.comQnexa/a/strong. According to its manufacturer, Vivus Inc., Qnexa is a diet pill which is composed of phentermine and topiramate. ... [view original]

• One of these products is Qnexa. According to its manufacturer, Vivus Inc., Qnexa is a diet pill which is composed of phentermine and topiramate. Phentermine is the most commonly used chemical for the handling of obesity. ... [view original]

• Clinical tests have shown that the Qnexa diet pill is effective and safe. This weight loss drug is taken orally, once a day. It has got a tiny dose formulation, so its manufacturer claims that it is well tolerated by its users. ... [view original]

• “The FDA's acceptance of the Qnexa NDA marks an important milestone in the development of Qnexa as a treatment for patients who are obese or overweight with co-morbidities,” stated Leland F. Wilson, chief executive officer for VIVUS. ... [view original]

• Qnexa (phentermine and topiramate) is a new drug in development for the treatment of obesity. Qnexa information includes news, clinical trial results and side effects. [view original]

• A small-scale, mid-stage trial of Qnexa, which is an experimental weight-loss medicine developed by Vivus Inc., has revealed that the drug can actually manage to reduce the incidence of sleep apnea events by about 69%, as confirmed by ... [view original]

• Youre searching for {0}? At oneview youll find recommended web sites and tips. [view original]

• One of these products is Qnexa. According to its manufacturer, Vivus Inc., Qnexa is a diet pill which is made of phentermine and topiramate. Phentermine is the most typically used chemical for the treatment of obesity. ... [view original]

• Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa (the phentermine/topiramate combination) will earn Decision ... [view original]

• One of these products is Qnexa. According to its manufacturer, Vivus Inc., Qnexa is a diet pill which is composed of phentermine and topiramate. Phentermine is the most frequently used chemical for the treatment of obesity. ... [view original]

• VIVUS, Inc. today announced that the US Food and Drug Administration (FDA) has accepted for filing the company's new drug application (NDA) for its investigational drug, Qnexa®, for the treatment of obesity. The target date for the FDA ... [view original]

• One of these products is Qnexa. According to its manufacturer, Vivus Inc., Qnexa is a diet pill which is composed of phentermine and topiramate. Phentermine is the most typically used chemical for the handling of obesity. ... [view original]

• Qnexa is an anti-obesity drug manufactured by Vivus, Inc. A 28 week study was done on 45 obese sleep apnea patients in 69% of the participants sleep apnea was reduced due to weight loss and a greater concentration of oxygen. ... [view original]

News results for: qnexa

wikio news

yahoo news

• ACCORD Lipid trial: New research into atherogenic dyslipidemia in.. Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprot..Date: Mon, 15 Mar 2010 04:53:08 GMT
  

  
• VIVUS granted three additional patents for Qnexa (News-Medical-Ne.. VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and ..Date: Mon, 08 Mar 2010 13:24:12 GMT
  

  
• Orexigen signs manufacturing deal for Contrave (AP via Yahoo! Fin.. Orexigen Therapeutics Inc. said Friday it signed a long-term manufacturing deal with drug manufacturer Patheon Inc. for producing the weight-loss drug Contrave.Date: Fri, 12 Mar 2010 22:20:03 GMT
  

  
• 5 Stocks That Laugh at Wall Street (The Motley Fool) These companies earnings handily beat analyst forecasts.Date: Fri, 12 Mar 2010 21:31:52 GMT
  

  
• Two Phase 3 studies of Sutent in advanced breast cancer fail to m.. Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of ..Date: Fri, 12 Mar 2010 10:08:18 GMT
  

  
• Orexigen Therapeutics narrows 4th-quarter loss (AP via Yahoo! Fin.. Obesity drug developer Orexigen Therapeutics Inc. reported a narrower fourth-quarter loss Tuesday after finishing clinical trials of its drug candidates Contrave and Empatic.Date: Tue, 09 Mar 2010 13:10:35 GMT
  

  
• Vivus's Qnexa Will Become Decision Resources' Clinical Gold Stand.. Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa (the phentermine/topiramate combination) will earn Decision Resources' propri..Date: Wed, 03 Mar 2010 16:34:15 GMT
  

  
• VIVUS Reports 2009 Fourth Quarter and Full-Year Financial Results.. VIVUS, Inc. today reported its financial results for the fourth quarter and year ended December 31, 2009.Date: Mon, 08 Mar 2010 21:01:00 GMT
  

  
• Vivus's Qnexa Will Become Decision Resources' Clinical Gold Stand.. Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa will earn Decision Resources' proprietary clinical gold standard in 2013 and ..Date: Tue, 02 Mar 2010 15:54:00 GMT
  

  
• FDA accepts for filing VIVUS' Qnexa NDA (News-Medical-Net) VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's new drug application (NDA) for its investigational drug, Qnexa®, for the treatment of obesity. The target date for the FDA to complete..Date: Mon, 01 Mar 2010 12:46:29 GMT
  

  

• topics
• tags
• terms of service
• privacy policy
• faqs
• about
• blog
•